Literature DB >> 7263927

Effect of obesity on gentamicin pharmacokinetics.

I Sketris, T Lesar, D E Zaske, R J Cipolle.   

Abstract

The effect of obesity on gentamicin disposition was studied in 60 obstetric and gynecologic patients receiving treatment for Gram-negative infections. Thirty patients whose body weights were within 20 per cent of their ideal body weight were the control group. Thirty additional patients had body weights at least 30 per cent greater than ideal body weight and were the obese group. The two groups had similar ages, heights, ideal body weights (IBW), lean body weights (LBW), and elimination rates of gentamicin. The distribution volumes, expressed as liters or standardized to ideal body weight, lean body weight, or total body weight, were significantly different in the controls from those in obese patients. The distribution volume averaged (+/- S.D.) 0.19 +/- 0.06 1./kg in controls. The contribution of excess weight to additional drug volume averaged (+/- S.D.) 0.05 +/- 0.161./kg. Excess weight thus contributes less volume per kilogram than ideal body weight or lean body weight. A substantial interpatient variability existed in the measured distribution volume for all groups. Measuring serum concentrations and adjusting a patient's dosage regimen are imperative to ensure therapeutic serum concentrations.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7263927     DOI: 10.1002/j.1552-4604.1981.tb01769.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  20 in total

1.  Effect of abnormal levels of serum components on antibiotic activity.

Authors:  B J Plotkin; M Wright; A Lima; L Gruenberg
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

2.  Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits.

Authors:  A H Groll; D Mickiene; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.

Authors:  M J Lind; J M Margison; T Cerny; N Thatcher; P M Wilkinson
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Measurement of glomerular filtration rate in obese patients: pitfalls and potential consequences on drug therapy.

Authors:  Grégoire Wuerzner; Murielle Bochud; Vittorio Giusti; Michel Burnier
Journal:  Obes Facts       Date:  2011-06-06       Impact factor: 3.942

Review 5.  Preventing surgical site infections after bariatric surgery: value of perioperative antibiotic regimens.

Authors:  Teena Chopra; Jing J Zhao; George Alangaden; Michael H Wood; Keith S Kaye
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2010-06       Impact factor: 2.217

6.  Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients.

Authors:  G Powis; P Reece; D L Ahmann; J N Ingle
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Comparison of non-kinetic and kinetic approaches to individualization of gentamicin dosage.

Authors:  Y M el-Sayed; S I Islam
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 8.  Drug disposition in obese humans. An update.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

9.  Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients.

Authors:  L A Bauer; W A Edwards; E P Dellinger; D A Simonowitz
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  Aminoglycoside dosing weight correction factors for patients of various body sizes.

Authors:  A M Traynor; A N Nafziger; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.